{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T16:29:50Z","timestamp":1758040190264,"version":"3.44.0"},"reference-count":56,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2012,12,1]],"date-time":"2012-12-01T00:00:00Z","timestamp":1354320000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,12,1]],"date-time":"2012-12-01T00:00:00Z","timestamp":1354320000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100015237","name":"Medicines Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015237","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004374","name":"Medtronic","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004374","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Heart Journal"],"published-print":{"date-parts":[[2012,12]]},"DOI":"10.1016\/j.ahj.2012.09.009","type":"journal-article","created":{"date-parts":[[2012,11,14]],"date-time":"2012-11-14T04:30:22Z","timestamp":1352867422000},"page":"810-816.e3","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Optimized Duration of Clopidogrel Therapy Following Treatment with the Endeavor Zotarolimus-Eluting Stent in Real-World Clinical Practice (OPTIMIZE) Trial: Rationale and design of a large-scale, randomized, multicenter study"],"prefix":"10.1016","volume":"164","clinical-trial-number":[{"clinical-trial-number":"nct01113372","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Fausto","family":"Feres","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ricardo A.","family":"Costa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deepak L.","family":"Bhatt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin B.","family":"Leon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto V.","family":"Botelho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"III","given":"Spencer B.","family":"King","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. Eduardo T.","family":"de Paula","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 A.","family":"Mangione","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"Jr.","given":"D\u00e9cio","family":"Salvadori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcos O.","family":"Gusm\u00e3o","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"Jr.","given":"H\u00e9lio","family":"Castello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"Jr.","given":"Eduardo","family":"Nicolela","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco A.","family":"Perin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fernando S.","family":"Devito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. Ant\u00f4nio","family":"Marin-Neto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandre","family":"Abizaid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ahj.2012.09.009_bb0005","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1056\/NEJMoa035071","article-title":"Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery","volume":"349","author":"Moses","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2012.09.009_bb0010","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/S0140-6736(07)60314-6","article-title":"Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study","volume":"369","author":"Daemen","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2012.09.009_bb0015","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1016\/j.amjmed.2006.01.023","article-title":"Late thrombosis of drug-eluting stents: a meta-analysis of randomized clinical trials","volume":"119","author":"Bavry","year":"2006","journal-title":"Am J Med"},{"key":"10.1016\/j.ahj.2012.09.009_bb0020","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.jcin.2009.10.022","article-title":"Incidence and predictors of very late (>or=4 years) major cardiac adverse events in the desire (drug-eluting stents in the real world)-late registry","volume":"3","author":"Costa","year":"2010","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.ahj.2012.09.009_bb0025","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1001\/jama.297.2.joc60179","article-title":"Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation","volume":"297","author":"Eisenstein","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.ahj.2012.09.009_bb0030","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1161\/CIRCULATIONAHA.106.180944","volume":"115","author":"Grines","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2012.09.009_bb0035","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/j.jcin.2009.09.012","article-title":"Identifying the \u201coptimal\u201d duration of dual antiplatelet therapy after drug-eluting stent revascularization","volume":"2","author":"Kandzari","year":"2009","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.ahj.2012.09.009_bb0040","first-page":"1047","article-title":"Antiplatelet therapy discontinuation following drug-eluting stent placement: dangers, reasons, and management recommendations","volume":"74","author":"Moussa","year":"2009","journal-title":"Catheter Cardiovasc Interv"},{"key":"10.1016\/j.ahj.2012.09.009_bb0045","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.amjcard.2010.10.045","article-title":"Identifying patients at risk for premature discontinuation of thienopyridine after coronary stent implantation","volume":"107","author":"Quadros","year":"2011","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ahj.2012.09.009_bb0050","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1111\/j.1540-8183.2006.00184.x","article-title":"Overview of pharmacology and clinical trials program with the zotarolimus-eluting endeavor stent","volume":"19","author":"Kandzari","year":"2006","journal-title":"J Interv Cardiol"},{"key":"10.1016\/j.ahj.2012.09.009_bb0055","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1016\/j.jcin.2010.08.021","article-title":"Long-term clinical outcomes with zotarolimus-eluting versus bare-metal coronary stents","volume":"3","author":"Mauri","year":"2010","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.ahj.2012.09.009_bb0060","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1161\/CIRCULATIONAHA.106.686048","article-title":"Incidence and predictors of drug-eluting stent thrombosis during and after discontinuation of thienopyridine treatment","volume":"116","author":"Airoldi","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2012.09.009_bb0065","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1056\/NEJMoa1001266","article-title":"Duration of dual antiplatelet therapy after implantation of drug-eluting stents","volume":"362","author":"Park","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2012.09.009_bb0070","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1056\/NEJMoa060989","article-title":"Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events","volume":"354","author":"Bhatt","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2012.09.009_bb0075","first-page":"283","article-title":"Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (plato): a randomised double-blind study","volume":"375","author":"Cannon","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2012.09.009_bb0080","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1016\/j.jacc.2008.12.073","article-title":"Bleeding, blood transfusion, and increased mortality after percutaneous coronary intervention: implications for contemporary practice","volume":"53","author":"Doyle","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2012.09.009_bb0085","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/j.ahj.2010.01.016","article-title":"Incidence, correlates, and clinical impact of nuisance bleeding after antiplatelet therapy for patients with drug-eluting stents","volume":"159","author":"Ben-Dor","year":"2010","journal-title":"Am Heart J"},{"key":"10.1016\/j.ahj.2012.09.009_bb0090","doi-asserted-by":"crossref","first-page":"2803","DOI":"10.1161\/CIRCULATIONAHA.106.618066","article-title":"Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the premier registry","volume":"113","author":"Spertus","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2012.09.009_bb0095","doi-asserted-by":"crossref","first-page":"45M","DOI":"10.1016\/j.amjcard.2007.08.021","article-title":"Zotarolimus-eluting stents in patients with native coronary artery disease: clinical and angiographic outcomes in 1,317 patients","volume":"100","author":"Gershlick","year":"2007","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ahj.2012.09.009_bb0100","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1590\/S0066-782X2011005000033","article-title":"Clinical outcomes by geographic region for patients implanted with the zotarolimus-eluting stent","volume":"96","author":"Lotan","year":"2011","journal-title":"Arq Bras Cardiol"},{"key":"10.1016\/j.ahj.2012.09.009_bb0105","doi-asserted-by":"crossref","first-page":"2314","DOI":"10.1253\/circj.CJ-10-0347","article-title":"Three-month dual antiplatelet therapy after implantation of zotarolimus-eluting stents","volume":"74","author":"Hahn","year":"2010","journal-title":"Circ J"},{"key":"10.1016\/j.ahj.2012.09.009_bb0110","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1161\/CIRCULATIONAHA.107.188208","volume":"117","author":"King","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2012.09.009_bb0115","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1161\/CIRCULATIONAHA.106.685313","article-title":"Clinical end points in coronary stent trials: a case for standardized definitions","volume":"115","author":"Cutlip","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2012.09.009_bb0120","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1016\/0735-1097(92)90312-B","volume":"19","author":"Topol","year":"1992","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2012.09.009_bb0125","doi-asserted-by":"crossref","first-page":"2736","DOI":"10.1161\/CIRCULATIONAHA.110.009449","article-title":"Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the bleeding academic research consortium","volume":"123","author":"Mehran","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2012.09.009_bb0130","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1016\/j.jcin.2009.10.001","article-title":"Safety and effectiveness of the endeavor zotarolimus-eluting stent in real-world clinical practice: 12-month data from the e-five registry","volume":"2","author":"Lotan","year":"2009","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.ahj.2012.09.009_bb0145","doi-asserted-by":"crossref","unstructured":"Mauri L, Kereiakes DJ, Normand SL, et al. Rationale and design of the dual antiplatelet therapy study, a prospective, multicenter, randomized, double-blind trial to assess the effectiveness and safety of 12 versus 30 months of dual antiplatelet therapy in subjects undergoing percutaneous coronary intervention with either drug-eluting stent or bare metal stent placement for the treatment of coronary artery lesions. Am Heart J 2010;160:1035\u20131041, 1041 e1031.","DOI":"10.1016\/j.ahj.2010.07.038"},{"key":"10.1016\/j.ahj.2012.09.009_bb0135","doi-asserted-by":"crossref","first-page":"620 e622","DOI":"10.1016\/j.ahj.2008.12.019","volume":"157","author":"Byrne","year":"2009","journal-title":"Am Heart J"},{"key":"10.1016\/j.ahj.2012.09.009_bb0150","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/j.ahj.2010.07.034","volume":"160","author":"Valgimigli","year":"2010","journal-title":"Am Heart J"},{"key":"10.1016\/j.ahj.2012.09.009_bb0155","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1161\/CIRCULATIONAHA.111.059022","article-title":"Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the efficacy of xience\/promus versus cypher to reduce late loss after stenting (excellent) randomized, multicenter study","volume":"125","author":"Gwon","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2012.09.009_bb0140","doi-asserted-by":"crossref","first-page":"902 e905","DOI":"10.1016\/j.ahj.2009.10.002","volume":"158","author":"Camenzind","year":"2009","journal-title":"Am Heart J"},{"key":"10.1016\/j.ahj.2012.09.009_bb0160","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1161\/CIRCULATIONAHA.111.071589","article-title":"Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial","volume":"125","author":"Valgimigli","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2012.09.009_bb0165","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1016\/j.jacc.2005.05.068","article-title":"Late incomplete stent apposition after sirolimus-eluting stent implantation: a serial intravascular ultrasound analysis","volume":"46","author":"Ako","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2012.09.009_bb0170","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1161\/01.CIR.0000155607.54922.16","article-title":"Incomplete stent apposition after implantation of paclitaxel-eluting stents or bare metal stents: insights from the randomized taxus ii trial","volume":"111","author":"Tanabe","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2012.09.009_bb0175","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1161\/CIRCULATIONAHA.105.563403","article-title":"Late stent malapposition after drug-eluting stent implantation: an intravascular ultrasound analysis with long-term follow-up","volume":"113","author":"Hong","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2012.09.009_bb0180","first-page":"83","article-title":"Very late thrombosis after drug-eluting stents","volume":"68","author":"Feres","year":"2006","journal-title":"Catheter Cardiovasc Interv"},{"key":"10.1016\/j.ahj.2012.09.009_bb0185","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1093\/eurheartj\/ehm114","article-title":"Late incomplete apposition after drug-eluting stent implantation: incidence and potential for adverse clinical outcomes","volume":"28","author":"Siqueira","year":"2007","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ahj.2012.09.009_bb0190","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1161\/CIRCULATIONAHA.109.854398","article-title":"Correlation of intravascular ultrasound findings with histopathological analysis of thrombus aspirates in patients with very late drug-eluting stent thrombosis","volume":"120","author":"Cook","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2012.09.009_bb0195","first-page":"157","article-title":"First-in-human study of the endeavor abt-578-eluting phosphorylcoline-encapsulated stent system in de novo native coronary artery lesions: ENDEAVOR I trial","volume":"1","author":"Meredith","year":"2005","journal-title":"EuroIntervention"},{"key":"10.1016\/j.ahj.2012.09.009_bb0200","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1161\/CIRCULATIONAHA.105.591206","article-title":"Randomized, double-blind, multicenter study of the endeavor zotarolimus-eluting phosphorylcholine-encapsulated stent for treatment of native coronary artery lesions: clinical and angiographic results of the endeavor ii trial","volume":"114","author":"Fajadet","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2012.09.009_bb0205","doi-asserted-by":"crossref","first-page":"355","DOI":"10.4244\/V5I3A56","article-title":"Angiographic and intravascular ultrasound findings following implantation of the endeavor zotarolimus-eluting stents in patients from the real-world clinical practice","volume":"5","author":"Feres","year":"2009","journal-title":"EuroIntervention"},{"key":"10.1016\/j.ahj.2012.09.009_bb0210","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.ahj.2007.08.008","article-title":"Comparison of vascular response to zotarolimus-eluting stent versus sirolimus-eluting stent: intravascular ultrasound results from endeavor iii","volume":"155","author":"Miyazawa","year":"2008","journal-title":"Am Heart J"},{"key":"10.1016\/j.ahj.2012.09.009_bb0215","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/j.jcin.2009.05.015","article-title":"Intravascular ultrasound results from the endeavor iv trial: randomized comparison between zotarolimus- and paclitaxel-eluting stents in patients with coronary artery disease","volume":"2","author":"Waseda","year":"2009","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.ahj.2012.09.009_bb0220","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1136\/heart.83.3.338","article-title":"Biocompatibility of phosphorylcholine coated stents in normal porcine coronary arteries","volume":"83","author":"Whelan","year":"2000","journal-title":"Heart"},{"key":"10.1016\/j.ahj.2012.09.009_bb0225","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1161\/01.CIR.103.2.192","article-title":"Lack of neointimal proliferation after implantation of sirolimus-coated stents in human coronary arteries: a quantitative coronary angiography and three-dimensional intravascular ultrasound study","volume":"103","author":"Sousa","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2012.09.009_bb0230","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa032441","article-title":"A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease","volume":"350","author":"Stone","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2012.09.009_bb0235","first-page":"58","article-title":"A randomized comparison of a durable polymer everolimus-eluting stent with a bare metal coronary stent: The spirit first trial","volume":"1","author":"Serruys","year":"2005","journal-title":"EuroIntervention"},{"key":"10.1016\/j.ahj.2012.09.009_bb0240","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1161\/01.CIR.94.7.1690","article-title":"Marked inflammatory sequelae to implantation of biodegradable and nonbiodegradable polymers in porcine coronary arteries","volume":"94","author":"van der Giessen","year":"1996","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2012.09.009_bb0245","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.jacc.2006.03.042","article-title":"Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk","volume":"48","author":"Joner","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2012.09.009_bb0250","doi-asserted-by":"crossref","first-page":"36M","DOI":"10.1016\/j.amjcard.2007.08.020","article-title":"The significance of preclinical evaluation of sirolimus-, paclitaxel-, and zotarolimus-eluting stents","volume":"100","author":"Nakazawa","year":"2007","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ahj.2012.09.009_bb0255","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1016\/j.jacc.2009.01.051","article-title":"A prospective, randomized, 6-month comparison of the coronary vasomotor response associated with a zotarolimus- versus a sirolimus-eluting stent: differential recovery of coronary endothelial dysfunction","volume":"53","author":"Kim","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2012.09.009_bb0260","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1536\/ihj.49.639","article-title":"Long-term coronary endothelial function after zotarolimus-eluting stent implantation. A 9 month comparison between zotarolimus-eluting and sirolimus-eluting stents","volume":"49","author":"Shin","year":"2008","journal-title":"Int Heart J"},{"key":"10.1016\/j.ahj.2012.09.009_bb0265","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1161\/CIRCINTERVENTIONS.108.797928","article-title":"Interference of drug-eluting stents with endothelium-dependent coronary vasomotion: evidence for device-specific responses","volume":"1","author":"Hamilos","year":"2008","journal-title":"Circ Cardiovasc Interv"},{"key":"10.1016\/j.ahj.2012.09.009_bb0270","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.jcin.2010.02.008","article-title":"Optical coherence tomography assessment of in vivo vascular response after implantation of overlapping bare-metal and drug-eluting stents","volume":"3","author":"Guagliumi","year":"2010","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.ahj.2012.09.009_bb0275","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1136\/hrt.2009.167759","article-title":"Optical coherence tomography evaluation of zotarolimus-eluting stents at 9-month follow-up: comparison with sirolimus-eluting stents","volume":"95","author":"Kim","year":"2009","journal-title":"Heart"},{"key":"10.1016\/j.ahj.2012.09.009_bb0280","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1016\/j.jcin.2009.10.006","article-title":"Evaluation in 3 months duration of neointimal coverage after zotarolimus-eluting stent implantation by optical coherence tomography: the ENDEAVOR OCT trial","volume":"2","author":"Kim","year":"2009","journal-title":"JACC Cardiovasc Interv"}],"container-title":["American Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870312006527?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870312006527?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T05:47:30Z","timestamp":1757569650000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002870312006527"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,12]]},"references-count":56,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2012,12]]}},"alternative-id":["S0002870312006527"],"URL":"https:\/\/doi.org\/10.1016\/j.ahj.2012.09.009","relation":{},"ISSN":["0002-8703"],"issn-type":[{"type":"print","value":"0002-8703"}],"subject":[],"published":{"date-parts":[[2012,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Optimized Duration of Clopidogrel Therapy Following Treatment with the Endeavor Zotarolimus-Eluting Stent in Real-World Clinical Practice (OPTIMIZE) Trial: Rationale and design of a large-scale, randomized, multicenter study","name":"articletitle","label":"Article Title"},{"value":"American Heart Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ahj.2012.09.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Mosby, Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}